Synapse - Gastrointestinal Oncology Service

Results (4744)

SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

Meeting Abstract

Ng, K.; Ou, F. S.; Zemla, T.; McCleary, N.; Kalyan, A.; Shusterman, M.; Vijayvergia, N.; Wu, C.; Cohen, S. A.; Pulsipher, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis

Meeting Abstract

O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
Pharmacoepidemiology and Drug Safety (2024)

Fulltext@MSK | Save

A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4

Meeting Abstract

Janjigian, Y. Y.; Lloyd, C.; de Giorgio-Miller, V. G.; Chang, Y. T.; Lee, J.
Annals of Oncology (2024)

Fulltext@MSK | Save

TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)—directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician's choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)

Meeting Abstract

Shitara, K.; Wainberg, Z. A.; van Cutsem, E.; Janjigian, Y. Y.; Xu, R. H.; Oh, D. Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Meeting Abstract

Kudo, M.; Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Breder, V. V.; Varela, M.; Crysler, O. V.; Bouattour, M.; Dao, V. T.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

EDGE-Gastric Arm A1: Phase II study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer

Meeting Abstract

Rha, S. Y.; Oh, D. Y.; Pelster, M.; Wainberg, Z. A.; Sison, A.; Scott, J.; Nelson, S.; Wishengrad, D.; Rhee, J.; Nuyten, D. S. A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

Meeting Abstract

Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Weber, P. E. Y.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Outcomes by comorbidities with tremelimumab and durvalumab in the phase 3 Himalaya study in unresectable hepatocellular carcinoma

Meeting Abstract

Rimassa, L.; Dayyani, F.; Kelley, R. K.; Sangro, B.; Chan, S. L.; McCoy, C. L.; Paskow, M. J.; Makowsky, M.; Gupta, C.; Ran, D.; more...
Hepatology (2024)

Fulltext@MSK | Save

Non-viral etiology subgroup of the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Meeting Abstract

Reig, M.; Tam, V.; Sangro, B.; Archambeaud, I.; Kelley, R. K.; Chan, S.; Kudo, M.; Masi, G.; Paskow, M.; Makowsky, M.; more...
Hepatology (2024)

Fulltext@MSK | Save

Five-year overall survival and overall survival by tumor response measures from the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Meeting Abstract

Rimassa, L.; Chan, S.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, T. V.; more...
Hepatology (2024)

Fulltext@MSK | Save